You just read:

New Clinical Trials, Pricing of Common Stock and Adjusted Conversion of Convertible Senior Notes - Research Report on Regeneron, Celldex, PDL BioPharma, Amedisys, and Exelixis

News provided by

Analysts' Corner

Dec 11, 2013, 08:00 ET